Shares of Sensus Healthcare Inc (NASDAQ:SRTS) have earned a consensus recommendation of “Buy” from the nine research firms that are presently covering the company, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has issued a hold rating and six have assigned a buy rating to the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $9.50.
A number of equities research analysts recently weighed in on SRTS shares. TheStreet downgraded Sensus Healthcare from a “c-” rating to a “d+” rating in a research report on Wednesday, May 22nd. ValuEngine upgraded shares of Sensus Healthcare from a “hold” rating to a “buy” rating in a research note on Saturday, August 10th. HC Wainwright restated a “buy” rating and set a $9.00 price target on shares of Sensus Healthcare in a research note on Monday, May 13th. Maxim Group set a $11.00 target price on shares of Sensus Healthcare and gave the company a “buy” rating in a research note on Friday, August 9th. Finally, Alliance Global Partners cut shares of Sensus Healthcare from a “buy” rating to a “neutral” rating in a research note on Friday, May 10th.
Hedge funds have recently bought and sold shares of the stock. Wells Fargo & Company MN bought a new position in Sensus Healthcare in the 2nd quarter worth approximately $30,000. Northern Trust Corp bought a new position in Sensus Healthcare in the 4th quarter worth approximately $86,000. BerganKDV Wealth Management LLC bought a new position in Sensus Healthcare in the 1st quarter worth approximately $88,000. B. Riley Wealth Management Inc. bought a new position in Sensus Healthcare in the 1st quarter worth approximately $117,000. Finally, Spark Investment Management LLC bought a new position in Sensus Healthcare in the 1st quarter worth approximately $155,000. Hedge funds and other institutional investors own 9.53% of the company’s stock.
Sensus Healthcare (NASDAQ:SRTS) last released its earnings results on Thursday, August 8th. The company reported $0.01 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.05) by $0.06. Sensus Healthcare had a negative return on equity of 8.82% and a negative net margin of 8.65%. The business had revenue of $7.48 million for the quarter, compared to the consensus estimate of $8.04 million. On average, equities research analysts anticipate that Sensus Healthcare will post -0.12 EPS for the current year.
About Sensus Healthcare
Sensus Healthcare, Inc manufactures and markets superficial radiation therapy devices to healthcare providers worldwide. It offers SRT-100, a photon X-ray low energy superficial radiotherapy system that provides patients an alternative to surgery for treating non-melanoma skin cancers; and SRT-100 Vision, which provides the user with a superficial radiation therapy-tailored treatment planning application that integrates the embedded high frequency ultrasound imaging module, volumetric tumor analysis, beam margins planning, and dosimetry parameters.
Recommended Story: Support Level
Receive News & Ratings for Sensus Healthcare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sensus Healthcare and related companies with MarketBeat.com's FREE daily email newsletter.